Chiesi group's new Biotech Center of Excellence under construction

24 November 2022

Privately-held Italian drugmaker Chiesi announced that its new center of excellence for the development and production of biologic drugs, currently under construction, will be built in Parma in the area of the production plant where the company is headquartered.

Expected to open and be fully operational in 2024, the center will specialize in the development and production of the active ingredients of monoclonal antibodies (MAbs) that are produced through recombinant DNA techniques starting from a single type of immune cell), enzymes and other proteins.

In the biotechnology space, sales in Chiesi’s global rare diseases portfolio have grown from 7% to 11% of total revenues of 2.42 billion euros ($2.65 billion) in 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK